临床试验/NCT07727993

NCT07727993尚未招募1 期

A Prospective, Open-Label, Single-Arm, Phase Ib/II Study of Neoadjuvant Propranolol Plus SOX Chemotherapy and Toripalimab in Patients With Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Ting Liu0 个研究点目标入组 49 人开始时间: 2026年8月1日最近更新: 2026年7月27日

适应症

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 49
主要终点: Pathological Complete Response (pCR) Rate

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

This is a single-center, prospective, open-label, single-arm, phase Ib/II study evaluating the safety and efficacy of neoadjuvant propranolol combined with SOX chemotherapy and toripalimab in patients with resectable locally advanced gastric or gastroesophageal junction adenocarcinoma. A total of 49 participants will be enrolled. Stage 1 includes an initial safety lead-in of 12 participants, followed by efficacy evaluation using a Simon two-stage design. Participants will receive propranolol, toripalimab, oxaliplatin, and S-1 during the neoadjuvant period, followed by curative-intent surgery.

The primary efficacy endpoint is pathological complete response. Secondary endpoints include safety and tolerability, major pathological response, R0 resection rate, event-free survival, recurrence-free survival, and overall survival. Exploratory analyses will assess changes in adrenergic stress markers, heart rate variability, peripheral immune parameters, β-adrenergic receptor signaling, and the tumor immune microenvironment.

研究设计

研究类型: Interventional
分配方式: Na
干预模型: Single Group
主要目的: Treatment
盲法: None

盲法说明

Pathological outcomes will be independently assessed by two gastrointestinal pathologists blinded to relevant treatment information. Disagreements will be resolved by a third pathologist.

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Voluntary participation in the study, with written informed consent, and willingness and ability to comply with the study treatment and follow-up requirements.
•Male or female participants aged 18 to 75 years.
•Histologically or cytologically confirmed gastric or gastroesophageal junction adenocarcinoma.Resectable locally advanced disease as determined by imaging assessment or a multidisciplinary team according to the eighth edition of the American Joint Committee on Cancer staging system, generally defined as cT3-4a with any N category, or any T category with node-positive disease, corresponding to stage II-III disease, without distant metastasis.
•Eastern Cooperative Oncology Group performance status of 0 or
•Acceptable cardiopulmonary function, including all of the following:
•(1)No clinically significant abnormality on electrocardiography; (2)Resting heart rate of at least 60 beats per minute; (3)Systolic blood pressure of at least 90 mmHg; (4)No progressive or decompensated cardiopulmonary disease; (5)Left ventricular ejection fraction of at least 50%. 6.Adequate organ function during screening, defined as follows:
•Absolute neutrophil count of at least 1.5 × 10⁹/L;
•Platelet count of at least 75 × 10⁹/L;
•Hemoglobin level of at least 90 g/L;
•Total bilirubin no greater than 1.5 times the upper limit of normal;
•Aspartate aminotransferase and alanine aminotransferase no greater than 2.5 times the upper limit of normal;
•Serum creatinine no greater than 1.5 times the upper limit of normal or creatinine clearance of at least 50 mL/min;
•International normalized ratio no greater than 1.5 times the upper limit of normal, unless the participant is receiving stable anticoagulation and is considered eligible by the investigator.
•7.Female participants of childbearing potential must have a negative pregnancy test during screening. Male and female participants of reproductive potential must agree to use effective contraception during the study and for at least 6 months after the last dose of study treatment.

排除标准

•Distant metastatic disease confirmed by imaging or diagnostic laparoscopy, including but not limited to peritoneal, hepatic, or bone metastases, or positive peritoneal cytology.
•Previous systemic anticancer treatment for the current malignancy, including chemotherapy, immunotherapy, or targeted therapy, or previous radiotherapy. Diagnostic endoscopy and biopsy are permitted.
•Grade 2 or higher peripheral neuropathy at baseline.
•A second primary malignancy requiring systemic treatment within the previous 3 years, except for adequately treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, low-risk thyroid cancer, or other malignancies considered cured.
•Inability to tolerate curative-intent surgery or study treatment, as determined by the investigator.
•Active autoimmune disease, or a clinically significant history of autoimmune disease requiring systemic immunosuppressive treatment within the previous 2 years. Participants with type 1 diabetes mellitus, stable thyroid disease requiring replacement therapy, vitiligo, or grade 2 or lower psoriasis not requiring systemic treatment may be eligible.
•Use of systemic corticosteroids at a prednisone-equivalent dose of at least 10 mg/day, or other systemic immunosuppressive agents, within 14 days before the planned initiation of immunotherapy. Physiologic replacement therapy, inhaled or topical corticosteroids, and short-term prophylactic treatment related to surgery are permitted.
•Active infection, including but not limited to active tuberculosis, uncontrolled hepatitis B virus or hepatitis C virus infection, human immunodeficiency virus infection, or another serious infection requiring intravenous antibiotic treatment.
•Any contraindication to propranolol, including:
•(1)Bronchial asthma or a risk of bronchospasm; (2)Diabetic ketoacidosis or metabolic acidosis; (3)Severe or symptomatic bradycardia; (4)Second- or third-degree atrioventricular block, sinoatrial block, or sick sinus syndrome; (5)Cardiogenic shock; (6)Right-sided heart failure caused by pulmonary hypertension; (7)Congestive heart failure; (8)Clinically significant hypotension; (9)Prolonged fasting; (10)Severe peripheral circulatory failure; (11)Untreated pheochromocytoma; (12)Variant angina; (13)Concomitant treatment with rizatriptan benzoate. 10.Moderate or severe chronic obstructive pulmonary disease with a recent acute exacerbation.
•11.Active upper gastrointestinal bleeding at baseline, melena or hematemesis within the previous 4 weeks, bleeding requiring blood transfusion or endoscopic hemostasis, uncontrolled peptic ulcer disease, or a high risk of recent bleeding as determined by the investigator.
•12.Requirement for continuous full-dose anticoagulation, dual antiplatelet therapy that cannot be interrupted, or a bleeding disorder that cannot be adequately managed during the perioperative period.
•13.Known hypersensitivity to propranolol, oxaliplatin, S-1 or fluoropyrimidines, toripalimab, or any of their excipients, or a history of a severe adverse reaction to any of these agents.
•14.Concomitant use of medications that cannot be discontinued or replaced and that may cause clinically significant interactions with propranolol, including verapamil, diltiazem, class I or class III antiarrhythmic agents, strong CYP2D6 or CYP1A2 inhibitors, or other medications considered by the investigator to pose a major drug-drug interaction risk.
•15.Uncontrolled bleeding disorder, or major surgery or serious trauma within 4 weeks before enrollment, excluding the curative-intent surgery planned as part of this study.
•16.Pregnancy or breastfeeding, or unwillingness to use the required contraceptive measures.
•17.Any medical, psychiatric, social, or other condition that, in the investigator's judgment, may compromise participant safety, treatment compliance, or completion of the required follow-up, including severe psychiatric illness, substance abuse, or inability to attend scheduled visits.

结局指标

主要结局

Pathological Complete Response (pCR) Rate

时间窗: At curative-intent surgery following completion of 3 neoadjuvant treatment cycles, approximately 13 to 15 weeks after treatment initiation.

The proportion of participants with no residual viable tumor cells in the resected primary tumor and all dissected regional lymph nodes following neoadjuvant treatment, corresponding to Becker grade 1a. Participants who do not undergo surgery or do not have an assessable pathological result will be classified as non-pCR in the intention-to-treat analysis.

次要结局

Dose-Limiting Toxicity (DLT) Rate During the Safety Lead-in(From the first dose of study treatment through 30 days after surgery)
Incidence of Treatment-Related Adverse Events(From the first dose of study treatment through at least 30 days after the last dose, or until treatment-related adverse events have resolved or stabilized)
Postoperative Complication Rate(Within 30 days after surgery)
Major Pathological Response (MPR) Rate(At curative-intent surgery following completion of neoadjuvant treatment, approximately 13 to 15 weeks after treatment initiation)
R0 Resection Rate(At curative-intent surgery following completion of neoadjuvant treatment, approximately 13 to 15 weeks after treatment initiation)
Event-Free Survival (EFS)(From the first dose of study treatment through up to 5 years)
Recurrence-Free Survival (RFS)(From curative-intent surgery through up to 5 years)
Overall Survival (OS)(From the first dose of study treatment through up to 5 years)

研究者

发起方

Ting Liu

申办方类型

Other

责任方

Sponsor Investigator

主要研究者

Ting Liu

West China Second University Hospital

相似试验

招募中

4 期

A Study to Assess the Safety of Addaven in Adult Patients Needing Intravenous Nutrition After Surgery

CTRI/2025/07/091425Fresenius Kabi India Pvt. Ltd188

招募中

1 期

CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia

NCT07371767Shanghai Jiao Tong University School of Medicine15

已完成

3 期

A study to see if Vaji Amrit Vati is safe and improves sexual problems in men.

CTRI/2025/11/096982Kudos Laboratories India30

招募中

不适用

Implantable Wireless Brain-Machine Interface System for Spinal Cord Injury: Efficacy and Safety StudySpinal Cord Injury

NCT07603752Shanghai StairMed Technology Co., Ltd.34

尚未招募

1 期

EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas

NCT07339527Sun Yat-sen University60